Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Xynomic Extends Phase III Abexinostat Trial to China and Europe

publication date: Mar 18, 2019

Xynomic, a US-Shanghai oncology pharma, announced that China, Spain and Poland authorities have approved Phase III trials of Xynomic's abexinostat, in combination with pazopanib, in patients with renal cell carcinoma (RCC). Abexinostat is a novel HDAC inhibitor. Xynomic has already started the same trial in the US and South Korea. Xynomic in-licensed the drug in 2017 (see story), but did not disclose details of the transaction. The molecule was developed by Pharmacyclics, which was acquired by AbbVie in 2015. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020